NEW YORK, July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether PTC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On June 28, 2024, PTC issue ...